Breakthrough for Adaptimmune as Tecelra gains US approval

Adaptimmune Therapeutics (Nasdaq: ADAP) has received Accelerated Approval from the US Food and Drug Administration (FDA) for Tecelra (afamitresgene autoleucel).

The nod makes Tecelra the first engineered cell therapy for a solid tumor cancer approved in the USA, as well as the first new therapy for synovial sarcoma in over a decade.

The therapy is approved for certain adults with unresectable or metastatic synovial sarcoma, a rare cancer that primarily affects young adults.